
---
title: '甘李药业：GZR4中国Ⅰ期临床试验完成首例受试者给药'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=996'
author: 证券时报网
comments: false
date: Thu, 01 Sep 2022 17:54:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=996'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603087" style="color: #2f67d1;text-decoration: none;" code="603087" target="_blank">甘李药业</a>(603087)9月1日晚间公告，公司自主研发的GZR4正在中国开展I期临床试验，于近日成功完成首例受试者给药。GZR4是<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603087" style="color: #2f67d1;text-decoration: none;" code="603087" target="_blank">甘李药业</a>在研的每周皮下注射给药一次的超长效胰岛素周制剂，适应症为糖尿病。</p>

                  
</div>
            